(2-ethyl-pyrazolo[1,5-a]pyridin-3-yl)methanol | 1189152-94-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 英文名称: (2-ethyl-pyrazolo[1,5-a]pyridin-3-yl)methanol
• 英文别名: (2-ethylpyrazolo[1,5-a]pyridin-3-yl)methanol
• CAS: 1189152-94-0
• 化学式: C₁₀H₁₂N₂O
• 分子量: 176.218
• InChiKey: SRRMEEQUFUISRU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  37.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (2-ethyl-pyrazolo[1,5-a]pyridin-3-yl)methanol 在 二氧化锰 作用下， 以 四氢呋喃 为溶剂， 反应 17.5h， 以to give 9.4 g (98%) of product, which的产率得到2-ethyl-pyrazolo[1,5-a]pyridine-3-carbaldehyde
  参考文献：
  名称：

  Hydroxamate-based inhibitors of deacetylases B

  摘要：

  本文涉及I式化合物及其药学上可接受的盐、水合物、酯和前药，其中R1、R2、R3、Y、Z和在此定义。本文还提供了制备I式化合物的方法，以及使用I式化合物治疗、抑制或预防完全或部分由去乙酰化酶介导的病理状况或疾病的方法。

  公开号：

  US08349883B2
• 作为产物：
  描述：

  2-戊炔酸乙酯 在 lithium aluminium tetrahydride 、 potassium carbonate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 (2-ethyl-pyrazolo[1,5-a]pyridin-3-yl)methanol
  参考文献：
  名称：

  Optimization of the in Vitro Cardiac Safety of Hydroxamate-Based Histone Deacetylase Inhibitors

  摘要：

  Histone deacetylase (HDAC) inhibitors have shown promise in treating various forms of cancer. However, many HDAC inhibitors from diverse structural classes have been associated with QT prolongation in humans. Inhibition of the human ether a-go-go related gene (hERG) channel has been associated with QT prolongation and fatal arrhythmias. To determine if the observed cardiac effects of HDAC inhibitors in humans is due to hERG blockade, a highly potent HDAC inhibitor devoid of hERG activity was required. Starting with dacinostat (LAQ824), a highly potent. HDAC inhibitor, we explored the SAR to determine the pharmacophores required for HDAC and hERG inhibition. We disclose here the results of these efforts where a high degree, of pharmacophore homology between these two targets was discovered. This, similarity prevented traditional strategies for mitigating hERG binding/modulation from being successful and novel approaches for reducing hERG inhibition were required. Using a hERG homology model, two compounds, 11r and 25i, were discovered to be highly efficacious with weak affinity for the hERG and other ion channels.

  DOI：

  10.1021/jm200388e

文献信息

• HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B
  申请人：SHULTZ Michael

  公开号：US20090247547A1

  公开（公告）日：2009-10-01

  The present teachings relate to compounds of Formula I: and pharmaceutically acceptable salts, hydrates, esters, and prodrugs thereof, wherein R 1 , R 2 , R 3 , Y, Z, and are as defined herein. The present teachings also provide methods of preparing compounds of Formula I and methods of using compounds of Formula I in treating, inhibiting, or preventing pathologic conditions or disorders mediated wholly or in part by deacetylases.

  目前的教导与化合物I的公式有关：及其药用盐、水合物、酯和前药，其中R1、R2、R3、Y、Z和如本文所定义的。目前的教导还提供了制备公式I化合物的方法以及使用公式I化合物治疗、抑制或预防完全或部分由去乙酰酶介导的病理状况或紊乱的方法。
• Hydroxamate-based inhibitors of deacetylases B
  申请人：Novartis AG

  公开号：US07943652B2

  公开（公告）日：2011-05-17

  The present teachings relate to compounds of Formula I: and pharmaceutically acceptable salts, hydrates, esters, and prodrugs thereof, wherein R1, R2, R3, Y, Z, and are as defined herein. The present teachings also provide methods of preparing compounds of Formula I and methods of using compounds of Formula I in treating, inhibiting, or preventing pathologic conditions or disorders mediated wholly or in part by deacetylases.

  本发明涉及公式I的化合物及其药学上可接受的盐、水合物、酯和前药，其中R1、R2、R3、Y、Z和在此定义。本发明还提供制备公式I化合物的方法以及使用公式I化合物治疗、抑制或预防完全或部分由去乙酰化酶介导的病理状况或疾病的方法。
• Hydroxamate-based inhibitors of deacetylases b
  申请人：Novartis AG

  公开号：EP2628726A1

  公开（公告）日：2013-08-21

  The present teachings relate to compounds of Formula I: and pharmaceutically acceptable salts, hydrates, esters, and prodrugs thereof, wherein R1, R2, R3, Y, Z, and are as defined herein. The present teachings also provide methods of preparing compounds of Formula I and methods of using compounds of Formula I in treating, inhibiting, or preventing pathologic conditions or disorders mediated wholly or in part by deacetylases.

  本教导涉及式 I 的化合物： 及其药学上可接受的盐、水合物、酯和原药，其中 R1、R2、R3、Y、Z 和如本文所定义。 本教导还提供了制备式 I 化合物的方法和使用式 I 化合物治疗、抑制或预防全部或部分由去乙酰化酶介导的病理状况或紊乱的方法。
• US7943652B2
  申请人：——

  公开号：US7943652B2

  公开（公告）日：2011-05-17
• US8349883B2
  申请人：——

  公开号：US8349883B2

  公开（公告）日：2013-01-08